Impact BioMedical Inc. (NYSE American: IBO)’s Post

Impact BioMedical Inc. (NYSE: IBO) Announces 3F™ US Patent Issue Impact BioMedical Inc. (NYSE American: IBO) is proud to announce that the U.S. Patent and Trademark Office has issued U.S. Patent No. 11,985,973, entitled “Insect Repelling Composition.” This patent was developed within our 3F™ technology platform and follows the previously granted U.S. Patent No. 11,246,310. The natural compositions within 3F™ “blind” insects to human presence by inhibiting their olfactory receptors. Potential applications include mosquito repellents and additives for products like detergents, shampoos, and lotions, making outdoor activities safer and more enjoyable. https://lnkd.in/ev_Zzni4 #ImpactBioMedical #3FTechnology #PatentIssue #HealthcareInnovation #InsectRepellent #NaturalProducts #NYSE #Biopharma 

💅 𝙄𝙉𝙊𝙇𝙀𝙓 𝙎𝙚𝙘𝙪𝙧𝙚𝙨 𝙀𝙪𝙧𝙤𝙥𝙚𝙖𝙣 𝙋𝙖𝙩𝙚𝙣𝙩 𝙛𝙤𝙧 𝙄𝙣𝙣𝙤𝙫𝙖𝙩𝙞𝙫𝙚, 𝙀𝙘𝙤-𝙁𝙧𝙞𝙚𝙣𝙙𝙡𝙮 𝙋𝙧𝙚𝙨𝙚𝙧𝙫𝙖𝙩𝙞𝙤𝙣 𝙏𝙚𝙘𝙝𝙣𝙤𝙡𝙤𝙜𝙮 ☀ 𝙄𝙣 𝙈𝙖𝙮 2024, With the recent issuance of European Patent EP3075401B1, Inolex is expanding its safe and ♻sustainable preservation platform. This patent covers methods of using the compositions to protect against #microbiological growth as well as paraben-free multifunctional compositions for topical 💄cosmetic, toiletry, and #pharmaceutical💊 formulations that require a vicinal diol and #caprylhydroxamicacid. The recently awarded patent for Inolex details this combination of #materials and the successful preservation of cosmetic items that results from it. Additionally, Inolex announces the expansion of its range of SpectrastatTM preservation products to include SpectrastatTM CHA, a powdered chelating agent that is 100% natural and not derived from palm oil🌴. Under the SpectrastatTM tradename, Inolex offers broad spectrum preservation systems that are built on top of these optimum combinations. 𝘽𝙧𝙤𝙬𝙨𝙚 𝙖𝙩 𝙤𝙪𝙧 𝙇𝙞𝙣𝙠𝙚𝙙 𝙍𝙚𝙥𝙤𝙧𝙩 👉: https://bit.ly/45ygGoV #Inolex #PreservationProducts #PreservationFormulations #EuropeanPatent #prophecymarketinsights

When Inherency Meets Obvious-to-Try: How Cytiva v. JSR Clarifies the Patent Obviousness Analysis The following link is to my recent article regarding the Federal Circuit’s decision in Cytiva BioProcess R&D AB v. JSR Corp., No. 2023-2074 (Fed. Cir. Dec. 4, 2024). In that decision, the court addressed obviousness challenges to multiple patents related to affinity chromatography, clarifying when a “lead compound” inquiry may be substituted with an “obvious-to-try” analysis and when the presence of inherent properties may obviate the need to demonstrate a reasonable expectation of success. The decision arose from inter partes review proceedings initiated by JSR, challenging patents held by Cytiva, before the Patent Trial and Appeal Board, which invalidated 79 composition claims across three patents while upholding four process claims. On appeal, the Federal Circuit affirmed the PTAB's invalidation of the 79 composition claims but reversed the PTAB’s decision on the four remaining process claims, concluding that all contested claims were unpatentable as obvious. https://lnkd.in/gcrCuCzX

When Inherency Meets Obvious-to-Try: How Cytiva v. JSR Clarifies the Patent Obviousness Analysis The following link is to my recent article regarding the Federal Circuit’s decision in Cytiva BioProcess R&D AB v. JSR Corp., No. 2023-2074 (Fed. Cir. Dec. 4, 2024). In that decision, the court addressed obviousness challenges to multiple patents related to affinity chromatography, clarifying when a “lead compound” inquiry may be substituted with an “obvious-to-try” analysis and when the presence of inherent properties may obviate the need to demonstrate a reasonable expectation of success. The decision arose from inter partes review proceedings initiated by JSR, challenging patents held by Cytiva, before the Patent Trial and Appeal Board, which invalidated 79 composition claims across three patents while upholding four process claims. On appeal, the Federal Circuit affirmed the PTAB's invalidation of the 79 composition claims but reversed the PTAB’s decision on the four remaining process claims, concluding that all contested claims were unpatentable as obvious. https://lnkd.in/g326Z3pK

Curious about provisional patent applications (PPAs)? Mark your calendars for August 28th! Join our cofounder Stephen Key and the USPTO's Silicon Valley Office next Wednesday at 4pm Pacific for a presentation featuring Patent Examiners Wade Miles and Ali Soroush, Esq.. Wade has been a Patent Examiner in AU 3771 since 2008, specializing in medical devices like stents, lancets, heart valves, and surgical robots. He became a Primary Examiner in 2014 and has contributed to USPTO initiatives, including the Patent Trial and Appeal Board, Technical Quality Assurance Shop, and Patent Training Academy. Ali brings over 17 years of experience as a Patent Examiner in biotechnology, with a special focus on pharmaceuticals, cosmetics, and herbicides. He’s contributed to several projects, including the development of Global Dossier and the implementation of WIPO standard ST.26 (presentation of nucleotide and amino acid sequence listings using xml). Why are PPAs important for inventors? Filing a PPA helps you begin establishing ownership of your invention. You can also use a PPA as a selling tool. Don't miss this chance to get your PPA questions answered by the USPTO! A special thank you to the USPTO’s Silicon Valley Office. Register for Inventors Online here: https://lnkd.in/e57d6gT2 #InventorsOnline #IGA #USPTO #PPA #IntellectualProperty #NewIdea

🔎 Navigating PFAS regulations is not just a compliance issue; it is essential for the safety and sustainability of medical devices.   Per- and poly-fluoroalkyl substances (PFAS) are a class of synthetic chemicals widely used across industries, including healthcare.   However, concerns about their persistence and potential adverse effects have prompted regulatory bodies, particularly in the Eurozone, to implement restrictions and deadlines for elimination.   How can medical device manufacturers address the compliance challenges posed by PFAS regulations?   Our blog explores strategies for identifying PFAS usage, assessing alternative options, managing PFAS-related technologies, and mitigating associated risks in the medical devices industry.   🔖 Read on: https://lnkd.in/gqGVFtgT #PFAS #MedicalDevices #EngineeringTheChange

A new white paper from TÜV SÜD informs medical device manufacturers about the planned bans and restrictions on the use of per- and polyfluoroalkyl substances (PFAS). What are the environmental and health risks associated with these synthetic chemicals? What challenges and opportunities are involved, and are there possible alternatives? And last but not least, what does this mean for supply chains? Click here for the related press release: http://spkl.io/60434Chex #TÜVSÜD #PFAS #MedicalDevice #Whitepaper

Granulation remains an essential manufacturing technology in the production of oral solid dosage forms since the majority of drug-loaded formulations are unsuitable for direct compression due to limited flowability and compactibility. Recently, twin-screw wet granulation (TSWG) has become one of the preferred granulation technique, as it can be easily integrated into a fully continuous manufacturing process. 💫 Binder selection is a crucial step in continuous twin-screw wet granulation (TSWG), as the material experiences a much shorter residence time in the granulator barrel compared to classical batch-wise granulation. Due to its high binder effectiveness at a low L/S-ratios PVA enables an efficient downstream processing. 💡 Learn more about it in our latest publication. Great work from Phaedra Denduyver, Chris Vervaet & Valérie Vanhoorne from Ghent University and Gudrun Birk & Alessandra Ambruosi from Merck Life Science. #pharma #manufacturing #continuousmanufacturing #CM #twinscrewgranulation #TSG #wetgranulation #excipients #polyvinylalcohol

Aseptic Coupling Devices A U.S. Patent for "Aseptic Coupling Devices" was awarded to CPC on July 23rd, 2024. The present invention is an aseptic coupling arrangement that can include a first coupling device and a second aseptic coupling device. In one embodiment, the first and second coupling devices are substantially similar, each having a main body defining a front face and a fluid passageway therethrough. A first connecting feature disposed on the main body of each coupling device may be provided for aligning and coupling the aseptic devices together. Each coupling device may also include a sealing member received in the main body and a membrane removably... https://lnkd.in/gCt2MF97 #aspenalert #biotech #bioprocess

Curious about provisional patent applications (PPAs)? Mark your calendars for August 28th! Join Inventors Groups of America and the USPTO’s Silicon Valley Office next Wednesday at 4pm Pacific for a presentation featuring Patent Examiners Wade Miles and Ali Soroush, Esq.! Wade has been a Patent Examiner in AU 3771 since 2008, specializing in medical devices like stents, lancets, heart valves, and surgical robots. He became a Primary Examiner in 2014 and has contributed to USPTO initiatives, including the Patent Trial and Appeal Board, Technical Quality Assurance Shop, and Patent Training Academy. Ali brings over 17 years of experience as a Patent Examiner in biotechnology, with a special focus on pharmaceuticals, cosmetics, and herbicides. He’s contributed to several projects, including the development of Global Dossier and the implementation of WIPO standard ST.26 (presentation of nucleotide and amino acid sequence listings using xml). Why are PPAs important for inventors? Filing a PPA helps you begin establishing ownership of your invention. You can also use a PPA as a selling tool. Don't miss this chance to get your PPA questions answered by the USPTO! A special thank you to the USPTO’s Silicon Valley Office. Register for Inventors Online here: https://lnkd.in/g_C_GMTF #InventorsOnline #IGA #USPTO #PPA #IntellectualProperty #NewIdea